195 related articles for article (PubMed ID: 15584500)
1. Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing/remitting multiple sclerosis.
Deisenhammer F; Giovannoni G
Mult Scler; 2004 Dec; 10(6):713-4; author reply 715. PubMed ID: 15584500
[No Abstract] [Full Text] [Related]
2. Interferon beta in multiple sclerosis: predicting response at an early stage.
Killestein J; Hartung HP
J Neurol Neurosurg Psychiatry; 2008 Jun; 79(6):616-7. PubMed ID: 18487553
[No Abstract] [Full Text] [Related]
3. Neutralizing antibodies to interferon-beta may persist after cessation of therapy: what impact could they have?
Polman C; Schellekens H; Killestein J
Mult Scler; 2006 Jun; 12(3):245-6. PubMed ID: 16764335
[No Abstract] [Full Text] [Related]
4. Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis.
Petkau AJ; White RA; Ebers GC; Reder AT; Sibley WA; Lublin FD; Paty DW;
Mult Scler; 2004 Apr; 10(2):126-38. PubMed ID: 15124756
[TBL] [Abstract][Full Text] [Related]
5. Interferon antibodies: do they alter the beneficial effects of beta-interferon upon relapse rate in multiple sclerosis?
Rudge P
Mult Scler; 2004 Apr; 10(2):123-5. PubMed ID: 15124755
[No Abstract] [Full Text] [Related]
6. Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS.
Reder AT; Ebers GC; Traboulsee A; Li D; Langdon D; Goodin DS; Bogumil T; Beckmann K; Konieczny A;
Neurology; 2010 Jun; 74(23):1877-85. PubMed ID: 20530324
[TBL] [Abstract][Full Text] [Related]
7. Effects of neutralizing antibodies to interferon beta in multiple sclerosis: a logical paradox.
Sørensen PS
Mult Scler; 2012 Feb; 18(2):131-2. PubMed ID: 22312007
[No Abstract] [Full Text] [Related]
8. Neutralizing and binding anti-interferon-beta (IFN-beta) antibodies. A comparison between IFN-beta-1a and IFN-beta-1b treatment in multiple sclerosis.
Kivisäkk P; Alm GV; Fredrikson S; Link H
Eur J Neurol; 2000 Jan; 7(1):27-34. PubMed ID: 10809912
[TBL] [Abstract][Full Text] [Related]
9. [Clinical importance of neutralising antibodies against interferon-beta in patients with relapsing-remitting multiple sclerosis].
Sørensen S; Koch-Henriksen NJ; Pedersen CR; Clemmesen KM; Bendtzen K; Frederiksen JL; Jensen K; Kristensen O; Petersen T; Rasmussen S; Ravnborg M; Stenager E;
Ugeskr Laeger; 2004 Oct; 166(41):3606-9. PubMed ID: 15515467
[No Abstract] [Full Text] [Related]
10. The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis.
Koch-Henriksen N; Sorensen PS; Bendtzen K; Flachs EM
Mult Scler; 2009 May; 15(5):601-5. PubMed ID: 19299439
[TBL] [Abstract][Full Text] [Related]
11. Statistical approaches to assessing the effects of neutralizing antibodies: IFNbeta-1b in the pivotal trial of relapsing-remitting multiple sclerosis.
Petkau AJ; White R
Neurology; 2003 Nov; 61(9 Suppl 5):S35-7. PubMed ID: 14610111
[TBL] [Abstract][Full Text] [Related]
12. [Betaferon in the treatment of multiple sclerosis: efficacy standards].
Totolian NA
Zh Nevrol Psikhiatr Im S S Korsakova; 2005; 105(7):63-6. PubMed ID: 16117152
[No Abstract] [Full Text] [Related]
13. The Danish National Project of interferon-beta treatment in relapsing-remitting multiple sclerosis. The Danish Multiple Sclerosis Group.
Koch-Henriksen N; Sørensen PS
Mult Scler; 2000 Jun; 6(3):172-5. PubMed ID: 10871828
[TBL] [Abstract][Full Text] [Related]
14. A case study on the effect of neutralizing antibodies to interferon beta 1b in multiple sclerosis patients followed for 3 years with monthly imaging.
Chiu AW; Ehrmantraut M; Richert ND; Ikonomidou VN; Pellegrini S; McFarland HF; Frank JA; Bagnato F
Clin Exp Immunol; 2007 Oct; 150(1):61-7. PubMed ID: 17666095
[TBL] [Abstract][Full Text] [Related]
15. [Interferons beta in patients with multiple sclerosis].
Vlasov IaV; Kuznetsova NI; Poverennova IE; Khivintseva EV
Zh Nevrol Psikhiatr Im S S Korsakova; 2005; 105(7):54-5. PubMed ID: 16117149
[No Abstract] [Full Text] [Related]
16. Neutralizing antibodies and the efficacy of interferon beta-1b in relapsing-remitting multiple sclerosis.
Petkau J; White R
Mult Scler; 1997 Dec; 3(6):402. PubMed ID: 9493643
[No Abstract] [Full Text] [Related]
17. Antibodies to IFN-beta: the Danish National IFN-beta Project.
Sorensen PS; Ross C; Clemmesen KM; Bendtzen K; Frederiksen JL; Jensen K; Kristensen O; Petersen T; Rasmussen S; Ravnborg M; Stenager E; Koch-Henriksen N; ;
Neurology; 2003 Nov; 61(9 Suppl 5):S27-8. PubMed ID: 14610108
[No Abstract] [Full Text] [Related]
18. Neutralizing antibodies to multiple sclerosis treatments.
Rossman HS
J Manag Care Pharm; 2004 Jun; 10(3 Suppl B):S12-9. PubMed ID: 15253685
[TBL] [Abstract][Full Text] [Related]
19. Fate of multiple sclerosis patients positive for neutralising antibodies towards interferon beta shifted to alternative treatments.
Malucchi S; Capobianco M; Gilli F; Marnetto F; Caldano M; Sala A; Bertolotto A
Neurol Sci; 2005 Dec; 26 Suppl 4():S213-4. PubMed ID: 16388361
[TBL] [Abstract][Full Text] [Related]
20. Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients.
Gneiss C; Tripp P; Reichartseder F; Egg R; Ehling R; Lutterotti A; Khalil M; Kuenz B; Mayringer I; Reindl M; Berger T; Deisenhammer F
Mult Scler; 2006 Dec; 12(6):731-7. PubMed ID: 17263000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
